Sunday 27 July 2025
  • About
  • Contact
  • Login
  • VC & Investment
  • M&A
  • AI
  • Podcasts
  • News
    • Pharmaceutical News
    • Biotechnology News
    • Generics News
    • Biosimilars news
    • In Brief
    • Legal
    • Company Pages
    • In The Boardroom
  • Insights
    • Analysis
    • Special Report
    • Interviews
    • Expert View
    • From Our Correspondent
    • One To Watch Companies
    • Digital Pharma
    • Pharma Leaders
  • Regulatory
    • FDA
    • EMA
    • Pricing, Reimbursement and Access
    • Regulation
    • Government Affairs
    • Trump Administration
  • Therapy Areas
    • Dermatologicals
    • Oncology
    • Neurological
    • Rare Diseases
    • Hematology
    • Cardio Vascular
    • Diabetes
    • Cell And Gene Therapy
  • Conferences
    • JPM Healthcare Conference
    • ESMO
    • ASCO
    • ASH
    • EULAR
    • AAIC
    • EASD
    • Forthcoming Events
  • Ones to Watch
  • About
  • Contact
  • Newsletter
  • Sign inSubscribe
Subscribe
  • Home
  • Ariad Pharma makes $14M share issue

Ariad Pharma makes $14M share issue

30 October 2006

Ariad Pharmaceuticals says that it has agreed to sell 3,112,945 shares of its common stock pursuant to its effective shelf registration statements in an underwritten offering. The underwriter has been granted an option to purchase up to an additional 466,942 shares of the firm's common stock to cover over-allotments.

Ariad expects the net proceeds from the sale of the shares will be around $14.0 million. All of the shares in the offering are being sold by the company.

Credit Suisse Securities (USA) is acting as sole underwriter for the offering. Ariad expects the deal to close on or about October 25, subject to customary closing conditions and, as a result of this transaction, the company will have no remaining shares available under shelf registration statements.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Try before you buy

 

Free

7 day trial access

Take a Free Trial
  • All the news that moves the needle in pharma and biotech
  • Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
  • Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Companies featured in this story

More ones to watch >


Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news

Today's issue

The week in pharma: action, reaction and insight – week to July 25
Biotechnology
The week in pharma: action, reaction and insight – week to July 25
27 July 2025
Pharmaceutical
FDA delays review of Bayer’s elinzanetant NDA
26 July 2025
Pharmaceutical
AstraZeneca’s Cristian Massacesi joins BMS executive team
26 July 2025
Biotechnology
Memo moving potravitug to Phase III despite primary endpoint miss
25 July 2025
Pharmaceutical
Impressive Humalog comparison sends Adocia shares skywards
25 July 2025
Biotechnology
Another negative development for Elevidys
25 July 2025
Pharmaceutical
New medicines recommended for approval by EMA’s CHMP
25 July 2025

Company Spotlight

A California-based biotech company aiming to deliver a new class of RNA therapeutics.






The Pharma Letter

39-43 Putney High Street, Putney
London, SW15 1SP
United Kingdom

  • About us
  • Contact
  • Subscribe
  • Sponsorship/advertising


  • Terms and Conditions
  • Privacy Policy
  • Twitter
  • Linkedin

Copyright © The Pharma Letter 2025   |   Headless Content Management with Blaze